

Haematologica  
HAEMATOL/2015/139329  
Version 4

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi

Stefano Sacchi, Raffaella Marcheselli, Alessia Bari, Gabriele Buda, Anna Lia Molinari, Luca Baldini, Daniele Vallisa, Marina Cesaretti, Pellegrino Musto, Sonia Ronconi, Giorgina Specchia, Franco Silvestris, Luciano Guardigni, Angela Ferrari, Annalisa Chiappella, Angelo Michele Carella, Armando Santoro, Francesco Di Raimondo, Luigi Marcheselli, and Samantha Pozzi

Disclosures: The authors report no potential conflicts of interest. The study was supported in part by the Associazione Angela Serra per la Ricerca sul Cancro, Modena, Italy and by research funding from Celgene, Summit, NJ; USA. Lenalidomide was supplied by Celgene, Summit, NJ; USA.

Contributions: SS and SP: conception and design of the study, interpretation of the data, final approval of the version to be published. LM, RM, and CM: statistical analysis, data collection, interpretation of data, and creation of tables and figures. SS, RM, LM; AB, and SP wrote the manuscript. SS, AB, GB, ALM, LB, DV, PM, SR, GS, FS, LG, AF, AC, AMC, AS, FDR and SP participated in the patients' care, data recording, and the interpretation of the data. All authors contributed critically to the drafting of the article and approved the final version.